EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening

Ilham M Alshiraihi, Ha Lam, Brennen T Troyer, Kristina N Tran, Malik Zohaib Ali, Daryl K Conner, Abigail Godelfer, Camron Pearce, Mary Jackson iD, Marcela Henao-Tamayo, Sara E Maloney Norcross, Bernd Meibohm iD und 3 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00475-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ilham M Alshiraihi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH Office of the Director, National Institute of Allergy and Infectious Diseases, Cystic Fibrosis Foundation Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus (MAB), a rapidly growing non-tuberculous mycobacterium, is becoming increasingly recognized as a significant pathogen affecting humans. These bacteria particularly impact individuals with cystic fibrosis (CF), non-CF bronchiectasis, and compromised immune systems. Treating pulmonary infections with MAB is challenging due to the bacteria’s inherent and acquired resistance to many antibiotics, including most anti-tuberculosis antibiotics. Antibiotic therapy of MAB infection is lengthy, involves multiple oral and parenteral administered drugs, induces significant toxicity, and, on many occasions, fails to cure. Consequently, developing more effective antibiotics has become a high priority. Preclinical studies to evaluate antibiotic efficacy against MAB are challenging because they fail to establish a progressive and sustained pulmonary infection in commonly used animal models. To address this issue, the course of MAB pulmonary infection was evaluated in 15 immunocompetent or deficient mouse strains. We report bacterial burden and histopathology and classify the models according to their ability to clear or sustain progressive infection beyond 28 days. We also examined the potential of these models for drug screening. Our findings provide a foundation for selecting suitable mouse models of pulmonary MAB infection for drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousAnti-Bacterial AgentsAnimalsMiceDisease Models, AnimalDrug Evaluation, PreclinicalLungFemaleMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Mycobacteriumabscessusdrug testingmodelsmousepreclinical

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Mycobacteria Research Laboratories, Non-Tuberculous Mycobacteria Center, Colorado State University, Fort Collins, Colorado, USA.
  • Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
  • Technology Advancement and Commercialization, RTI International, Research Triangle Park, North Carolina, USA.
  • Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Mary Jackson, Bernd Meibohm, Richard E Lee, Mercedes Gonzalez-Juarrero, Andres Obregon-Henao

Förderung

  • NIH Office of the Director
  • National Institute of Allergy and Infectious Diseases
  • Cystic Fibrosis Foundation Therapeutics
  • NIAID NIH HHS
  • NIH HHS

Zitieren

APA

Alshiraihi, I. M., Lam, H., Troyer, B. T., Tran, K. N., Zohaib Ali, M., Conner, D. K., Godelfer, A., Pearce, C., Jackson, M., Henao-Tamayo, M., Norcross, S. E. M., Meibohm, B., Lee, R. E., Gonzalez-Juarrero, M., & Obregon-Henao, A. (2025). Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00475-25

Vancouver

Alshiraihi IM, Lam H, Troyer BT, Tran KN, Zohaib Ali M, Conner DK, et al. Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00475-25

BibTeX
@article{Alshiraihi2025,
  author = {Alshiraihi, Ilham M and Lam, Ha and Troyer, Brennen T and Tran, Kristina N and Zohaib Ali, Malik and Conner, Daryl K and Godelfer, Abigail and Pearce, Camron and Jackson, Mary and Henao-Tamayo, Marcela and Norcross, Sara E Maloney and Meibohm, Bernd and Lee, Richard E and Gonzalez-Juarrero, Mercedes and Obregon-Henao, Andres},
  title = {Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00475-25}
}
Kostenlos starten →